Company Overview and News

 
NAB sets aside $314m for compensation

1h perthnow.com.au
NAB is setting aside $314 million for customer remediation programs, becoming the latest big bank to take a big profit hit due to compensation.
NAUBF NAB NASXF NABZY

 
NAB profit to take $314m hit from extra customer compensation

2h abc.net.au
National Australia Bank has confirmed its profit will be slashed by a further $314 million due to extra "customer remediation" costs.
NAUBF NAB NASXF NABZY

 
Markets Live: ASX poised for flat day

2h theage.com.au
National Australia Bank will pay an additional $314 million after tax for customer remediation, it tells the market this morning. This will reduce cash earnings for the second half of 2018 by about $261 million. And it will reduce earnings from discontinued operations by about $53 million.
NAUBF NAB NASXF NABZY

 
Markets Live: ASX poised for flat day

2h watoday.com.au
National Australia Bank will pay an additional $314 million after tax for customer remediation, it tells the market this morning. This will reduce cash earnings for the second half of 2018 by about $261 million. And it will reduce earnings from discontinued operations by about $53 million.
NAUBF NAB NASXF NABZY

 
Markets Live: ASX poised for flat day

2h smh.com.au
National Australia Bank will pay an additional $314 million after tax for customer remediation, it tells the market this morning. This will reduce cash earnings for the second half of 2018 by about $261 million. And it will reduce earnings from discontinued operations by about $53 million.
NAUBF NAB NASXF NABZY

 
NAB flags extra $314m in customer remediation costs

3h theage.com.au
National Australia Bank on Tuesday flagged additional costs of $314 million after tax in connection with its customer remediation program.
NAUBF NAB NASXF NABZY

 
NAB flags extra $314m in customer remediation costs

3h watoday.com.au
National Australia Bank on Tuesday flagged additional costs of $314 million after tax in connection with its customer remediation program.
NAUBF NAB NASXF NABZY

 
NAB flags extra $314m in customer remediation costs

3h smh.com.au
National Australia Bank on Tuesday flagged additional costs of $314 million after tax in connection with its customer remediation program.
NAUBF NAB NASXF NABZY

 
Asian stocks extend slide on plethora of risks

15h malaymail
TOKYO, Oct 15 — Asian stocks started the week on the back foot today, with investors still in a gloomy mood after several days of market turbulence sparked by trade rows and a spat over the US central bank.
NAUBF NAB NASXF NABZY

 
Asian stocks extend slide on plethora of risks

16h channelnewsasia
TOKYO: Asian stocks started the week on the back foot on Monday (Oct 15), with investors still in a gloomy mood after several days of market turbulence sparked by trade rows and a spat over the US central bank.
NAUBF NAB NASXF NABZY

 
Atlas makes board changes

19h businessnews.com.au
Atlas Iron has announced a raft of board changes, including the appointment of former state government tourism boss Stephen Wood and National Australia Bank executive Spiro Pappas.
NAUBF AGO ATLGF AGODY NAB NASXF NABZY

 
Aussie Post in ultimatum to big bank

22h ntnews.com.au
Supplied footage obtained Friday, October 12, 2018, of ANZ bank chief executive Shayne Elliot speaking at a parliamentary inquiry in Canberra. Mr Elliot acknowledges ANZ has engaged in "misconduct" and says it is "completely unacceptable" that the bank has caused harm to its customers. "As CEO since 2016 I am ultimately accountable for this," Mr Elliot says. "In the past ANZ has not focused sufficiently on formally holding executives to account.
NAUBF NAB NASXF NABZY

 
'Shock not over' as Asian stocks extend slide

22h channelnewsasia
TOKYO: Asian stocks opened the week on the back foot Monday (Oct 15), with investors still in gloomy mood after several days of market turbulence sparked by trade rows and a spat over the US central bank.
NAUBF NAB NASXF NABZY

 
Australia Post throws down gauntlet to ANZ, threatens post office black ban

22h perthnow.com.au
THOUSANDS of ANZ customers could effectively be left without a local branch amid a stand-off between the bank and Australia Post.
NAUBF NAB NASXF NABZY

 
Executive pay punishment looms at Telstra AGM

2018-10-12 theage.com.au
A tough year already for Telstra chief executive Andy Penn is likely to get even worse on Tuesday. Penn and his embattled executive team will then face irate investors in Sydney at what is shaping as the ugliest annual general meeting since the AMP bloodfest in May.
NAUBF TPGTF NAB NASXF TPPTY TPM NABZY OGFGF WHC OGFGY ORG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...